TheraNyM Biologics opens ₹1,200 crore manufacturing facility near Hyderabad

A ₹1,200 crore manufacturing installation of generic drugmaker Aurobindo Pharma’s subsidiary TheraNyM Biologics adjacent Hyderabad, with a imaginable to make much than 1,500 jobs for the section youth, was opened connected Wednesday (June 3, 2026).

Telangana IT and Industries Minister D. Sridhar Babu formally inaugurated the installation that volition manufacture medicines utilized successful the attraction of crab and different life-threatening diseases. The products volition beryllium exported to respective planetary markets, including the U.S., the Minister’s bureau said aft the lawsuit successful which Health Minister Damodar Rajanarasimha and others participated.

The installation has been established astatine Borpatla colony successful Hathnoora Mandal of neighbouring Sangareddy district. It is expected to make employment opportunities for much than 1,500 section youth, Mr.Sridhar Babu’s bureau said.

With the accomplishment of TheraNyM Biologics, the planetary estimation and worth of the Made successful Telangana marque successful the Life Sciences assemblage are expected to go adjacent stronger, it said. The State authorities has been reiterating its absorption connected consolidating Telangana’s presumption arsenic a preferred destination for Life Sciences companies.

Two years ago, Aurobindo Pharma had announced the signing of a maestro work statement betwixt TheraNym and planetary pharma large Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) for declaration manufacturing of biologicals.

TheraNym, the genitor institution said, volition manufacture the products and proviso to MSD and intends to put astir ₹1,000 crore for establishing a manufacturing installation with ample standard bioreactors for immoderate mammalian compartment civilization merchandise and a vial filling isolator enactment for commercialized cause merchandise manufacturing up to 25-30 mn vials per annum.

Earlier this year, Aurobindo Pharma said TheraNym Biologics volition found a greenfield task for commissioning a ample standard mammalian cause substance manufacturing installation (Unit 2) lodging a full of 60 KL bioreactor capacities with an investment of astir $150-175 million. This followed the signing of merchandise schedule, further to the existing declaration manufacturing operations (CMO) agreement, with MSD, it had said.